Abstract：As abnormal pubertal development, central precocious puberty (CPP) is manifested by the secondary sexual characteristics, skeletal maturation, and physical development in advance. It ultimately affects the adult height of children, even producing some psychological and behavioral problems such as fear and anxiety. Currently, gonadotropin releasing hormone analogue (GnRHa) is recognized as the best medicine worldwide for treating CPP in order to increase children’s final adult height; however, it has some adverse effects on the growth and development of children. This paper reviews the effects of CPP and GnRHa on children's physical and sexual development, with the aim of increasing physicians awareness of this disease and the safety of medication.
Soriano-Guillen L, Corripio R, Labarta JI, et al. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigratio[J]. Clin Endocrinol Metab, 2010, 95(9): 4305-4313.
[2]
Massart F, Seppia P, Pardi D, et al, High incidence of central precocious puberty in a bounded geographic area of northwest Tuscany: an estrogen disrupter epidemic? [J]. Gynecol Endocrinol, 2005, 20(2): 92-98.
Franceschi R, Gaudino R, Marcolongo A, et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty[J]. Fertil Steril, 2010, 93(4): 1185-1191.
Ko JH, Lee HS, Lim JS, et al. Changes in bone mineral density and bodycomposition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist[J]. Horm Res Paediatr, 2011, 75(3): 174-179.
Preamrudee P, Suphasit R, Mahachoklertwattana P. Adult height, body massindex and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment[J]. Gynecol Endocrinol, 2011, 27(8): 524-528.
Prete G, Couto-Silva AC, Trivin C, et al. Idiopathic central precocious puberty in girls: presentation factors[J]. BMC Pediatrics, 2008, 8(27): 1-8．
[15]
Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche and menarche attainment in children with normal and elevated body mass index[J]. Pediatrics, 2009, 123(1): 84-88.
[16]
Nar A, Demirtas E, Ayhan A, et al. Effects of bilateral ovariectomy and estrogen replacement therapy on serum leptin, sex hormone binding globulinand insulin like growth factor-I levels[J]. Gynecol Endocrinol, 2009, 25(12): 773-778.
Laron Z. Is obesity associated with early sexual maturation? [J]. Pediatrics, 2004, 113(1): 171-172.
[19]
Kaplowitz BP. Link between body fat and the timing of puberty[J]. Pediatrics, 2008, 121(3): 208-217.
[20]
Su PH, Yang SF, Yu JS, et al. Study of leptin levels and gene polymorphisms in patients with central precocious puberty[J]. Pediatr Res, 2012, 71(4): 361-367.
[21]
Donato J Jr, Cravo RM, Frazao R, et al. Leptin's effect on puberty in mice is relayed by the ventral premammillary nucleus and does not require signaling in Kiss1 neurons[J]. Clin Invest, 2011, 121(1): 355-368.
[22]
Sorensen K, Aksglaede L, Petersen JH, et al. Serum IGF1 and insulin levels in girls with normal and precocious puberty[J]. Eur J Endocrinol, 2012,166(5): 903-910.
Rhie YJ, Lee KH, Eun SH, et al. Serum kisspeptin levels in Korean girls with central precocious puberty[J]. Korean Med Sci, 2011, 26(7): 927-931.
[26]
Wolinska-Witort E, Martynska L, Chmielowska M, et al. The evaluation ofestradiol and leptin action on the activity of the somatotropic and gonadotropic axes in peripubertal female rats[J]. Neuro Endocrinol Lett, 2012, 33(2): 138-148.
[27]
Hsieh CC, Trichopoulos D, Katsouyanni K, et al. Age at menarche, age atmenopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study[J]. Int J Cancer 1990, 46(15): 796-800.
Lewis KA, Eugster EA. Random luteinizing hormone often remains pubertal in children treated with the histrelin Implant for central precocious puberty[J]. J Pediatr, 2013, 162(3): 562-565.
[30]
Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty[J]. J Pediatr, 2011, 159(6): 982-987.
[31]
Allali S, Lemaire P, Couto-Silva AC, et al. Predicting the adult height of girls with central precocious puberty[J]. Med Sci Moni, 2011, 17(6): 41-48.
[32]
Lee PA, Neely EK, Fuqu J, et al. Efficacy of leuprolide acetate 1-month depot central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study[J]. Int J Pediatric Endocrinol, 2011, 2011(1): 1-7.
[33]
Massart F, Federico G, Harrel JC, et al. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty[J]. Neuroendocrinology, 2009, 90(3): 307-314.
Brito VN, Latronico AC, Cukier P, et al. Factors determining normal adultheight in girls with gonadotropin-dependent precocious puberty treated withdepot gonadotropin releasing hormone analogs[J]. Clin Endocrinol Metab, 2008, 93(7): 2662-2669.
[37]
Carel JC. Management of short stature with GnRH agonist and co-treatment with growth hormone：a controversial issue[J]. Mol Cell Endocrinol, 2006, 25(254-255): 226-233.
Taccilar ME, Bilir P, Akinci A, et al. The effect of gonadotropin-releasing hormone analog treatment (leuprolide) on body fat distribution in idiopathic central precocious puberty[J]. Tur J Pediatric, 2011, 53(1): 27-33.
[41]
Chiocca E, Dati E, Baroncelli GI, et al. Body mass index and body composition in adolescents treated with gonadotropin releasin hormone analogue triptorelin depot for central precocious puberty: data at near final height[J]. Neuroendocrinology, 2009, 89(4): 441-447.
[42]
Karamizadeh Z, Tabebordbar M, Saki F, et al. The side effects of gonadotropin-releasing hormone analog (diphereline) in treatment of idiopathic central precocious puberty[J]. Acta Medica Iranica, 2013, 51(1): 41-46.
[43]
Lee HS, Park HK, Ko JH, et al. Impact of body mass index on luteinizing hormone secretion in gonadotropin releasing hormone stimulation tests ofboys experiencing precocious puberty[J]. Neuroendocrinology, 2013, 97(3): 225-231.
[44]
Glab E, Barg E, Wikiera B, et al. Influence of GnRH analog therapy on body mass in central precocious puberty[J]. Pediatr Endocrinol Diabetes Metab, 2009, 15(1): 7-11.
[45]
Park HK, Lee HS, Ko JH, et al. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty[J]. Clin Endocrinol, 2012, 77(5): 743-748.
[46]
Inman M, Hursh BE, Mokashi A, et al. Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin releasing hormone agonist therapy for the treatment of central precocious puberty[J]. Horm Res Paediatr, 2013, 80(1): 64-68.
[47]
Seminara S, Nanni L, Generoso M, et al. Effect of treatment with cyproterone acetate on uterine bleeding at the beginning of GnRH analogue therapy in girls with idiopathic central precocious puberty[J]. Horm Res Paediatr, 2010, 73(5): 386-388.
[48]
Seminara S, Nanni L, Generoso M, et al. Effect of treatment with cyproterone acetate on uterine bleeding at the beginning of GnRH analogue therapy in girls with idiopathic central precocious puberty[J]. Horm Res Paediatr, 2010, 73(5): 386-389.
[49]
Naor Z, Jabbour HN, Naidich M, et al. Reciprocal cross talk between gonadotropin-releasing hormone（GnRH）and prostaglandin receptors regulates GnRH receptor expression and differential gonadotropin secretion[J]. Mol Endocrinol, 2007, 21(2): 524-537.
[50]
Kauschansky A, Orvieto R, Yeshaya A, et al. Insight: prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist: a proposed mechanism and management plan[J]. J Pediatr Adolesc Gynecol, 2011, 24(6): 365-367.
[51]
Heger S, Muller M, Ranke M, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function[J]. Mol Cell Endocrinol, 2006, 25(254-255): 217-220.
[52]
Chiavaroli V, Liberati MD, Antonio F, et al. GnRH analog therapy in girlswith early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome[J]. Eur J Endocrinol, 2010, 163(1): 55-62.
